Total Funding
59
16
Total FundingSeries D raised
Growth Score
-16 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
573701
Serenex is a drug discovery and development company focused on oncology.
Ian Howes: CFO & Senior VP Corporate DevelopmentPast Role: Akebia Therapeutics, CFO & VP Corporate Development
Pfizer
About the Company
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops
SNX-1012, a product for oral mucositis in solid tumor patients.
Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
